PDCD1 and metastatic melanoma: This retrospective multicenter cohort study analyzed patients treated with adjuvant anti–PD-1 therapy for advanced and metastatic melanoma between 2015 and 2022 from 6 institutions in the US and Australia with at least 18 months of evaluable follow-up after treatment cessation (range, 18.2 to 70.4 months).